Cellbion wins South Korea IND clearance for phase 3 prostate cancer trial of Lu-177 DGUL

Bitget2026/09/28 22:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cellbion secured South Korea MFDS clearance to start a Phase 3 trial of Lutetium-177 DGUL in metastatic castration-resistant prostate cancer.
The study targets 150 patients in Korea, testing add-on Lutetium-177 DGUL versus best supportive care or standard of care.
Approval date: Sept. 28, 2026; planned study completion: Jan. 31, 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellbion Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260929900003), on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cellbion wins South Korea IND clearance for phase 3 prostate cancer trial of Lu-177 DGUL

You may also like

Crypto prices